Universidad Peruana Cayetano Heredia

Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III-IV Canine Oral Malignant Melanoma.

Mostrar el registro sencillo del ítem

dc.contributor.author Tellado, Matías
dc.contributor.author De Robertis, Mariangela
dc.contributor.author Montagna, Daniela
dc.contributor.author Giovannini, Daniela
dc.contributor.author Salgado Nuñez del Prado, Sergio Fernando
dc.contributor.author Michinski, Sebastián
dc.contributor.author Signori, Emanuela
dc.contributor.author Maglietti, Felipe
dc.date.accessioned 2023-07-18T16:18:56Z
dc.date.available 2023-07-18T16:18:56Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/13930
dc.description.abstract Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7-14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III-IV inoperable canine oral malignant melanoma. en_US
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartofseries Vaccines (Basel)
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Electroporation en_US
dc.subject Electrogene transfer en_US
dc.subject Immune response en_US
dc.subject Cancer en_US
dc.subject Dog en_US
dc.subject ECT en_US
dc.subject EGT en_US
dc.subject Immunotherapy en_US
dc.subject.mesh Electroporación
dc.subject.mesh Técnicas de Transferencia de Gen
dc.subject.mesh Inmunidad
dc.subject.mesh Neoplasias
dc.subject.mesh Perros
dc.subject.mesh Terapia Electroconvulsiva
dc.subject.mesh Inmunoterapia
dc.title Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III-IV Canine Oral Malignant Melanoma. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.3390/vaccines11061033
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.03
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.05
dc.relation.issn 2076-393X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas